News articles about Ophthotech (NASDAQ:OPHT) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ophthotech earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.4767946660444 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Several research analysts have weighed in on the company. JPMorgan Chase & Co. cut Ophthotech from a “neutral” rating to an “underweight” rating in a research report on Monday, March 19th. Zacks Investment Research cut Ophthotech from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 7th. TheStreet cut Ophthotech from a “c” rating to a “d+” rating in a research report on Friday, March 2nd. Finally, ValuEngine cut Ophthotech from a “buy” rating to a “hold” rating in a research report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $3.50.

Ophthotech traded up $0.04, hitting $3.13, during trading hours on Wednesday, Marketbeat reports. 5,035 shares of the stock were exchanged, compared to its average volume of 1,529,605. The stock has a market capitalization of $116.89 million, a price-to-earnings ratio of 0.99 and a beta of 1.38. Ophthotech has a 12 month low of $2.25 and a 12 month high of $4.50.

Ophthotech (NASDAQ:OPHT) last posted its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.04. Ophthotech had a negative return on equity of 1,485.62% and a net margin of 26.69%. equities research analysts expect that Ophthotech will post -1.63 earnings per share for the current fiscal year.

Ophthotech Company Profile

Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula.

Insider Buying and Selling by Quarter for Ophthotech (NASDAQ:OPHT)

Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with's FREE daily email newsletter.